Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data-Reference-Cited by-同舟云学术

Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data

Published:2022-04 Issue: Volume:62 Page:1-9
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Bernat-Peguera Adrià,Trigueros Macedonia,Ferrando-Díez Angélica,Ibáñez Cristina,Bystrup Sara,Martínez-Cardús Anna,Margelí Mireia,Martínez-Balibrea Eva

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference47 articles.

1. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3;Balselga;Nat Rev Cancer [Internet],2009

2. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005

3. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities;Yarden;Eur J Cancer (Oxf Engl : 1990) [Internet],2001

4. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolf;J Clin Oncol : Off J Am Soc Clin Oncol [Internet],2013

5. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update;Wolff;J Clin Oncol [Internet],2018

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study;Expert Opinion on Biological Therapy;2024-04-02

2. Biosimilar in Breast Cancer: A Narrative Review;Cureus;2024-01-23

3. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China;JAMA Network Open;2023-10-12

4. Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer;EMJ Oncology;2023-10-02

5. Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer;EMJ Oncology;2023-10-02